Parkinson’s Disease Therapeutics Market Top Trends 2027 | Orion Corporation, Roche, AbbVie Inc., Acadia Pharmaceuticals, Amneal Pharmaceuticals
The Parkinson’s disease therapeutics market expansion would be augmented by extensive investments in R&D activities to uplift the development in the treatment of the disease. Reportedly, the Parkinson’s Foundation in 2020 invested nearly US$3.5 million in 34 research programs to support the efforts of promising scientists in the field of Parkinson’s disease (PD).
The Parkinson’s Disease Biomarkers Program (PDBP) funding endorse discovery projects to encourage the identification of developments and diagnostic biomarkers for the disease. Consequently, a substantial rise in funding towards R&D programs for the development of novel therapies will propel the demand for Parkinson’s therapeutics in the forthcoming years.
Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/2724
As per the recent statistics, the number of Americans diagnosed with PD was nearly 60,000 each year. Also, the number of people living with PD reported at over 10 million globally. According to a Global Market Insights, Inc., analysis report, global Parkinson’s disease therapeutics market size is projected to surpass US$8 billion by 2027.
The Parkinson’s disease therapeutics industry progression would further be augmented by the growing awareness among the population about the disease. Early diagnosis of the disease plays a key role in providing effective treatment to the affected patient. The lack of awareness and knowledge among people about Parkinson’s disease has led to the commencement of numerous awareness programs. For instance, World Parkinson’s Day is an initiative to encourage new research and treatment programs by creating awareness among the population pertaining to the disease.
The dopamine agonists segment accounted for a considerable revenue share at nearly US$694 million in 2020. The medication is highly preferred in the treatment of Parkinson’s disease owing to its resemblance to the effect of dopamine in the brain. The medication does not contain any side effects such as dyskinesia, which is mostly caused by other drugs. These drugs are adopted to improve the condition-related symptoms by indicating the presence of dopamine in the brain, therefore propelling industry growth.
The adult patient segment of the Parkinson’s disease therapeutics industry is expected to grow at 6.9% CAGR up to 2027. The segment expansion is majorly attributed to the growing vulnerability to idiopathic Parkinson’s disease among the aging population base. The rapidly growing aging population base across the globe has resulted in a large number of patients being affected by Parkinson’s disease.
The Brazil Parkinson’s disease therapeutics industry was over US$90 million in 2020. The regional industry progression is predominantly driven by robust economic expansion, substantial development in healthcare infrastructure, and rising incidences of Parkinson’s disease in the country. Also, the presence of dynamic pharmacology and biotechnology research sector backed by the Brazilian government will provide exponential growth opportunities to the regional industry.
Moreover, the health policy in Brazil is formulated to promote adjunction and collaboration among scientists and several therapeutic research projects. Consequently, the existence of advanced healthcare infrastructure will foster Parkinson’s disease therapeutics industry landscape in the region.
Request for customization @ https://www.gminsights.com/roc/2724
Leading firms functioning in the Parkinson’s disease therapeutics industry include Teva Pharmaceutical, Acadia Pharmaceuticals, AbbVie Inc., UCB, Amneal Pharmaceuticals, Roche, and Orion Corporation, among others.
These industry firms are engaged in implementing several strategies including R&D, the inclusion of advanced technology, and others to produce novel products to lead the competitive market scenario. For example, the U.S.-based ACADIA Pharmaceuticals, Inc. received approval for its NUPLAZID drug from FDA in 2016. The recognition from the regulatory body helped the company in augmenting the product portfolio and uplifting its customer base.
Partial Chapter of the Table of Content
Chapter 5 Parkinson’s Disease Therapeutics Market, By Route of Administration
5.1 Key segment trends
5.2.1 Market size, by region, 2016 - 2027 (USD Million)
5.3.1 Market size, by region, 2016 - 2027 (USD Million)
5.4.1 Market size, by region, 2016 - 2027 (USD Million)
5.5.1 Market size, by region, 2016 - 2027 (USD Million)
Chapter 6 Parkinson’s Disease Therapeutics Market, By Patient
6.1 Key segment trends
6.2.1 Market size, by region, 2016 - 2027 (USD Million)
6.3.1 Market size, by region, 2016 - 2027 (USD Million)
Browse full table of contents (TOC) of this report @ https://www.gminsights.com/toc/detail/parkinsons-disease-therapeutics-market
Related Report @ https://www.gminsights.com/industry-analysis/femtech-market
Corporate Sales, USA
Global Market Insights, Inc.
Toll Free: 1-888-689-0688
About Global Market Insights, Inc.
Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson’s Disease Therapeutics Market Top Trends 2027 | Orion Corporation, Roche, AbbVie Inc., Acadia Pharmaceuticals, Amneal Pharmaceuticals here
News-ID: 2278948 • Views: 693
More Releases from Global Market Insight, Inc
Inhalation Anesthesia Market Projections 2025 | Abbott, Baxter International, Ha …
Global inhalation anesthesia market is poised to gain massive momentum over the forecast period of 2019 to 2025. This can be credited to the significant rise in product adoption primarily driven by increasing surgical procedures related to respiratory, neurological and chronic disorders. Additionally, supportive reimbursement scenario across developed countries and availability of several insurance schemes for quick and affordable surgical procedures will increase the application of inhalational anesthetics, thereby supporting
Health Insurance Market Trends 2025 | Aetna, Blue Cross Blue Shield Companies, C …
Regular occurrences of long-term diseases will bolster the health insurance industry trends in the next few years. This rise can be attributed to the changing dietary habits, lack of physical activities, poor nutrition, excessive alcohol use, and tobacco consumption. Various Government-backed initiatives by several programs like State Children's Health Insurance Program, Medicaid, Life programs, Department of Defense, TRICARE are employed to provide health insurance policies. Centers for Medicare & Medicaid
Ambulance Services Market Outlook 2021-2026 | Acadian Ambulance Service, BVG Ind …
The global ambulance services market is estimated to foresee momentous growth through the forthcoming time period owing to an upsurge in road accidents. Additionally, the growing prevalence of chronic diseases and increasing medical tourism trend is further slated to augment the overall market size through 2026. Additionally, the introduction of new ambulance models and launch of new technologies that focus on the enhancement of ambulatory care is likely to proliferate
Biosimilars Market Forecast 2025 | Amgen, Biocon, Biogen, Boehringer Ingelheim, …
Touted to be an intrinsic sub-vertical of healthcare and medical devices industry, biosimilars market is poised to record phenomenal gains in the upcoming years owing to the fact that these play a pivotal role in augmenting public health issue by addressing the customer needs to a much larger extent. Numerous reports suggest that biosimilars would result in overall potential savings of nearly USD 100 billion by the end of 2020,
More Releases for Parkinson’s
Parkinson’s Disease Therapeutics Market 2021 | Detailed Report
Global Parkinson’s Disease Therapeutics Market 2021-2027, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. An exclusive data offered in this report is collected by research and industry experts team. Get Free Sample PDF (including full TOC, Tables and
Parkinson’s Disease Treatment Market 2021 | Detailed Report
Parkinson’s Disease Treatment Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027. Get Free Sample PDF (including full TOC, Tables and Figures) of Parkinsons Disease Treatment Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5024082 The report provides a comprehensive analysis of company profiles listed below: - Teva - Roche - Prothena - Acorda
Parkinson’s disease Therapeutics Parkinson’s disease Therapeutics Market to …
This report studies the global Parkinson's Disease Therapeutics market, analyzes and researches the Parkinson's Disease Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like GSK Novartis Boehringer Ingelheim Teva Pharmaceutical Abbvie ….. Ask for sample copy @ https://www.researchtrades.com/request-sample/1199125 Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast Asia Market segment by Type, Parkinson's Disease Therapeutics can be split into Medications Therapeutics Medical Devices Therapeutics Buy
US Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in the United States in recent years and it most likely to continue rising in the near future. It has been estimated that at least 500,000 people in the United States currently have been diagnosed with this disease. The society pays a significant amount towards treating this disease in the country. It is estimated that the total cost to the nation exceeds
Europe Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been estimated that currently, more than 1 million in Europe are affected by Parkinson’s disease. This figure is most likely to double by 2030. Among the most common neurodegenerative disease (after Alzheimer’s disease), Parkinson’s is the second most common and it is expected that
Parkinson’s Disease - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Parkinson’s Disease - Heat Map and Analysis to its growing collection of premium market research reports. Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the progressive loss of muscular control, leading to resting tremor, rigidity, akinesia and postural reflex impairment. PD is an age-related disorder; symptoms typically begin to first appear in patients in their mid-sixties,